- Stronger Yuan Needed for Global Rebalancing: IMF Chief
- Washington Not Trying to Contain China: Obama
- Japan Third Quarter GDP Jumps; 2010 Growth May Slow
- Quiz: How Much Do You Know About Green?
- Citi Rejects Terra Firma's Latest Bid to Save EMI: Report
- Analysis: APEC Nations Back Face-Saving Climate Plan
- BlackRock: Central Banks To Be Net Buyers of Gold
- GM to Start Repaying $6.7 Billion US Government Loan
- Canon to Buy Dutch Oce in $2.2 Billion Deal
- Warren Buffett to CNBC: 'I Haven't Bought American Express In Years'
- CNBC Video: Warren Buffett & Bill Gates - Keeping American Great
- U.S. Stocks Rally for the Second Straight Week
- Dollar is Not Plunging—So 'Calm Down': Market Strategist
- Strategists Say Markets Have More Upside — But How Much?
- Hirschhorn: Risk-Averse Traders
- Roginsky: A Funny Thing Happened on the Way to Financial Reform
- This Year's Biggest Thanksgiving Leftover: Cash
- TV Series Inks Unique Deal For Fight
- Obama prods China to accept ‘universal rights’
- Airbus parent EADS reports Q3 loss on weak dollar
- Calif. man set for hearing in wine warehouse fire
- Census: Small US cities lose luster in downturn
- Dakotas might see record sunflower yields
- Emirates chief: Boeing, Airbus orders possible
- Remittances of Filipinos abroad up 8.6 percent
- Source: GM to begin repaying aid by year-end
- MasterCard holiday gift campaign pairs with Amazon
Text Size 
NEW YORK - A day after drugmaker Merck & Co. completed its $41.1 billion purchase of rival Schering-Plough Corp., Fitch Ratings Service on Wednesday cut its ratings on Merck and upgraded Schering-Plough.
Fitch downgraded Merck's issue default rating by one notch, to A+ from AA-, and also lowered its senior unsecured debt rating on Merck. At the same time, it raised Schering-Plough's issuer default rating to A+ from BBB+ and raised Schering-Plough's senior unsecured debt rating.
The deal involved about $8.5 billion in debt.
Fitch expects the Whitehouse Station, N.J., company's revenue to fall next year after the patent on the blood pressure drug Cozaar expires. It expects growth in the following years. The outlooks on both companies are now stable, the company said.
In afternoon trading, Merck shares climbed $1.95, or 6.4 percent, to $32.62.
Print
Email
- Where, what, how.
- Warren Buffett and Bill Gates spoke to Columbia students, and Buffett made the students a startling offer.
- For the chief of cable company Comcast, growth has been about making deals – generally very large deals.
- Some companies may start using insurance to shift carbon risk from their balance sheets to maybe... yours?
- The president and founder of Genesis Today wants to improve America’s health, and thinks Wal-Mart can help.
- Switzerland's privacy watchdog is taking legal action to force Google to make changes to its Street View service.
Data is a real-time snapshot *Data is delayed at least 15 minutes